Interest of Branched Chain Amino Acids Associated With a Respiratory Rehabilitation Program in Patients Broncho Chronic Obstructive Pulmonary Disease

Not Applicable

Completed

• Conditions: Broncho Chronic Obstructive Pulmonary Disease
• Interventions: Drug: Placebos; Drug: Amino Acids

• Registration Number: NCT03644836
• Lead Sponsor: Poitiers University Hospital

Brief Summary

Respiratory rehabilitation is one of the main treatments for COPD in the early stages of the disease (Stage 2 of GOLD) with a recognized effect on improving the capacity of the patients to exert effort by fighting against deconditioning. the effort. This treatment also improves the quality of life of patients and reduces the risk of respiratory exacerbations. The patients are very often malnourished and various studies have proposed the addition of oral supplementation such as hormone therapy (testosterone) to improve the exercise performance of these atrophied muscles. The use of branched-chain amino acids (AARs) such as valine, leucine, isoleucine in this indication can be fully justified because they stimulate protein synthesis and promote muscle maintenance and repair.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01-21
• Primary Completion: 2018-01-31
• Study Completion: 2018-03-05
• Study First Submitted: 2018-08-06
• Study First Submitted QC: 2018-08-21
• Study First Posted: 2018-08-23
• Status Verified: 2019-02
• Last Update Submitted: 2019-02-19
• Last Update Posted: 2019-02-20

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Patients Broncho Chronic Obstructive Pulmonary Disease in stages 2 and 3 of the GOLD classification, whose Maximum Expiratory Volume on the first second is between 30% and 80% of the expected theoretical value, associated with a maximal expiratory volume ratio on the first Second / Vital Capacity less than or equal to 70% of the expected theoretical value.
• Patients of both sexes, aged 40 to 80 years
• In case of active smoking, patients must commit to interrupting it during the respiratory rehabilitation program that will be proposed to them in this study

Exclusion Criteria

• • Age <40 years or> 80 years
• Patients with a contraindication to exercise,
• Phenylketonuria
• Patients treated with long-term oxygen therapy and / or home ventilation will not be included.
• Patients with acute respiratory decompensation in the three months prior to inclusion.
• Patients with known allergy to milk, gluten, soy, egg and nuts
• Patients taking part in another clinical trial or who have participated in a clinical trial in the 3 months preceding this study.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Retraining with respiratory effort+ placebo	Placebos	-
Retraining with respiratory effort+ amino acids	Amino Acids	-

Primary Outcome Measures

Name	Time	Method
maximum oxygene uptake	after 6 weeks of treatment	maximum oxygene uptake measured during intensive exercise

Trial Locations

Locations (1)

Chu de Poitiers; 🇫🇷 Poitiers, France